The deep and durable efficacy data, including activity after prior approved CAR-T, are encouraging for CB-011's differentiation. Watch for the dose expansion data in H2 2026, which will further inform the registrational path. The company's ability to fund a pivotal Phase 3 is a key risk given its ~$178M market cap.
CRBU drugs
CRBU drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · Jun 11 $1.66entry
- T+1 · 5mo ago −3.92%α −4.46% · $1.60
- T+5 · 5mo ago −1.20%α −1.64% · $1.64
- T+20 · 4mo ago +16.87%α +14.98% · $1.94
- T+60 · due 2mo ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Caribou Biosciences reported longer follow-up data from the CaMMouflage Phase 1 trial of CB-011, an off-the-shelf BCMA-targeted CAR-T therapy for relapsed/refractory multiple myeloma. In the BCMA-naïve recommended dose expansion cohort (n=12), results showed a 92% ORR, 83% CR/≥CR rate, 91% MRD negativity, and 50% of patients sustaining ≥CR at 15 months, with a manageable safety profile. These data will be presented at EHA on June 14, 2026, and initial dose expansion data in both BCMA-naïve and BCMA-exposed patients are expected in H2 2026.
Key Facts
- Single dose of CB-011 at the 450M cell RDE produced 92% ORR, 83% CR/≥CR rate, 91% MRD negativity in BCMA-naïve patients (n=12).
- 50% of patients in the BCMA-naïve RDE cohort maintained ≥CR at 15 months; median follow-up 17.7 months.
- A case study of a patient who had failed approved autologous CAR-T (cilta-cel) achieved CR by day 28 with CB-011.
- Safety profile was manageable with no GvHD, parkinsonism, or cranial nerve palsies; one (8%) ≥Gr 3 CRS, no ≥Gr 3 ICANS at RDE.
- EHA oral presentation scheduled for June 14, 2026; initial dose expansion data expected in H2 2026.
- CB-011 has FDA RMAT, Fast Track, and Orphan Drug designations for r/r multiple myeloma.
Financial Impact
No financial figures were disclosed. These are clinical data only.
Risk Factors
- CaMMouflage Phase 1 is still ongoing with a small dataset (n=48 total); larger expansion cohorts may show different results.
- CB-011 faces competition from approved BCMA CAR-Ts and other allogeneic approaches; commercial adoption is uncertain.
- Caribou's limited financial resources and history of operating losses could constrain further development and pivotal trial funding.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3310377 |
Track record
13 reports on CRBU
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 5, 202611d ago 8-K Bearish 7/10 Entry $0.4487 Now $0.3530 +21.33% settles Dec 7
- Oct 6, 20265w ago 8-K Bearish 7/10 Entry $0.6174 to $0.4444 Now $0.3530 +42.82% ▲ +28.02% +26.68% vs SPY
- Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $1.34 to $0.5190 Now $0.3530 −73.66% ▼ −61.27% −60.71% vs SPY
- Jun 11, 202622w ago 8-K Bullish 6/10 Entry $1.66 to $1.94 Now $0.3530 −78.73% ▲ +16.87% +14.98% vs SPY
- Jun 11, 202622w ago Press Release Bullish 7/10 Viewing Entry $1.66 to $1.94 Now $0.3530 −78.73% ▲ +16.87% +14.98% vs SPY
- Jun 5, 202623w ago DEFA14A Neutral 2/10 Entry $1.84 to $1.83 Now $0.3530 −80.82% ▼ −0.54% −2.17% vs SPY
- Apr 24, 202629w ago DEFA14A Neutral 3/10 Entry $2.13 to $2.16 Now $0.3530 −83.43% ▲ +1.41% −3.55% vs SPY
- Mar 5, 202636w ago 8-K Mixed 5/10 Entry $1.82 to $1.95 Now $0.3530 −80.60% ▲ +7.14% +9.19% vs SPY
- Mar 5, 202636w ago Press Release Mixed 6/10 Entry $1.82 to $1.95 Now $0.3530 −80.60% ▲ +7.14% +9.19% vs SPY
- Feb 28, 202637w ago Institutional Cluster Neutral 5/10 Entry $1.84 to $1.72 Now $0.3530 −80.82% ▼ −6.52% +1.42% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers